APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Growth and Trends Forecast to 2032

20 December 2025102 pages

Choose your research edition.

Industry ResearchDiphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Astellas Pharma US, Emergent BioSolutions Inc, Merck Sharp & Dohme Corp, Protein Sciences Corporation, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Company

Astellas Pharma US

Emergent BioSolutions Inc

Merck Sharp & Dohme Corp

Protein Sciences Corporation

Sanofi Pasteur

Seqirus

AstraZeneca

GlaxoSmithKline

Pfizer Inc

Lanzhou Institute of Biological Products Co., Ltd

Novartis AG

Johnson & Johnson

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Type

Immune DTaP Vaccine

Therapy DTaP Vaccine

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Application

Adult

Pediatric

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Immune DTaP Vaccine Table 2. Major Company of Therapy DTaP Vaccine Table 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 5. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (W Units) Table 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 15. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 17. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 19. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 21. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (W Units) Table 23. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends Table 25. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers Table 26. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges Table 27. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Company (2021-2026) & (W Units) Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Company (2021-2026) Table 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Company Production Sites and Headquarters Table 35. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Company, Product Type & Application Table 36. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026) & (W Units) Table 41. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2027-2032) & (W Units) Table 46. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 52. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (W Units) Table 57. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 62. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 64. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 66. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 68. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (W Units) Table 70. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Astellas Pharma US Company Information Table 72. Astellas Pharma US Business Overview Table 73. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 75. Astellas Pharma US Recent Development Table 76. Emergent BioSolutions Inc Company Information Table 77. Emergent BioSolutions Inc Business Overview Table 78. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 80. Emergent BioSolutions Inc Recent Development Table 81. Merck Sharp & Dohme Corp Company Information Table 82. Merck Sharp & Dohme Corp Business Overview Table 83. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 85. Merck Sharp & Dohme Corp Recent Development Table 86. Protein Sciences Corporation Company Information Table 87. Protein Sciences Corporation Business Overview Table 88. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 90. Protein Sciences Corporation Recent Development Table 91. Sanofi Pasteur Company Information Table 92. Sanofi Pasteur Business Overview Table 93. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 95. Sanofi Pasteur Recent Development Table 96. Seqirus Company Information Table 97. Seqirus Business Overview Table 98. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 100. Seqirus Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 105. AstraZeneca Recent Development Table 106. GlaxoSmithKline Company Information Table 107. GlaxoSmithKline Business Overview Table 108. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 110. GlaxoSmithKline Recent Development Table 111. Pfizer Inc Company Information Table 112. Pfizer Inc Business Overview Table 113. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 115. Pfizer Inc Recent Development Table 116. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 117. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 118. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 120. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 121. Novartis AG Company Information Table 122. Novartis AG Business Overview Table 123. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 125. Novartis AG Recent Development Table 126. Johnson & Johnson Company Information Table 127. Johnson & Johnson Business Overview Table 128. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio Table 130. Johnson & Johnson Recent Development Table 131. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 132. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 133. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2026) Table 134. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032) & (W Units) Table 135. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Country (2027-2032) Table 136. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country (2021-2026) Table 139. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Country (2027-2032) Table 141. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 142. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 143. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2026) Table 144. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032) & (W Units) Table 145. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country (2021-2026) Table 149. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 153. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032) & (W Units) Table 155. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country (2021-2026) Table 159. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Country (2027-2032) Table 161. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 162. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 163. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2026) Table 164. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032) & (W Units) Table 165. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country (2021-2026) Table 169. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026) & (W Units) Table 173. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032) & (W Units) Table 175. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country (2021-2026) Table 179. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List Table 184. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Image Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2032) & (W Units) Figure 5. Immune DTaP Vaccine Image Figure 6. Global Immune DTaP Vaccine Sales YoY Growth (2021-2032) & (W Units) Figure 7. Therapy DTaP Vaccine Image Figure 8. Global Therapy DTaP Vaccine Sales YoY Growth (2021-2032) & (W Units) Figure 9. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Adult Image Figure 24. Global Adult Sales YoY Growth (2021-2032) & (W Units) Figure 25. Pediatric Image Figure 26. Global Pediatric Sales YoY Growth (2021-2032) & (W Units) Figure 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application 2025 VS 2032 Figure 29. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2025 Figure 30. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2025 Figure 31. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application in 2025 Figure 39. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 40. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Immune DTaP Vaccine
  • Therapy DTaP Vaccine
Applications
  • Adult
  • Pediatric
Companies covered
  • Astellas Pharma US
  • Emergent BioSolutions Inc
  • Merck Sharp & Dohme Corp
  • Protein Sciences Corporation
  • Sanofi Pasteur
  • Seqirus
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer Inc
  • Lanzhou Institute of Biological Products Co., Ltd
  • Novartis AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Type
  6. 1.3.1 Immune DTaP Vaccine
  7. 1.3.2 Therapy DTaP Vaccine
  8. 1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
  9. 1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
  2. 2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Drivers
  3. 2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Opportunities and Challenges
  4. 2.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2021-2026)
  4. 3.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Company, Product Type & Application
  7. 3.7 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Tier 1, Tier 2, and Tier 3
4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Regional Status and Outlook
  1. 4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Region
  3. 4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application
  1. 5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market by Application
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
  5. 5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Astellas Pharma US
  2. 6.1.1 Astellas Pharma US Company Information
  3. 6.1.2 Astellas Pharma US Business Overview
  4. 6.1.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  6. 6.1.5 Astellas Pharma US Recent Developments
  7. 6.2 Emergent BioSolutions Inc
  8. 6.2.1 Emergent BioSolutions Inc Company Information
  9. 6.2.2 Emergent BioSolutions Inc Business Overview
  10. 6.2.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  12. 6.2.5 Emergent BioSolutions Inc Recent Developments
  13. 6.3 Merck Sharp & Dohme Corp
  14. 6.3.1 Merck Sharp & Dohme Corp Company Information
  15. 6.3.2 Merck Sharp & Dohme Corp Business Overview
  16. 6.3.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  18. 6.3.5 Merck Sharp & Dohme Corp Recent Developments
  19. 6.4 Protein Sciences Corporation
  20. 6.4.1 Protein Sciences Corporation Company Information
  21. 6.4.2 Protein Sciences Corporation Business Overview
  22. 6.4.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  24. 6.4.5 Protein Sciences Corporation Recent Developments
  25. 6.5 Sanofi Pasteur
  26. 6.5.1 Sanofi Pasteur Company Information
  27. 6.5.2 Sanofi Pasteur Business Overview
  28. 6.5.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  30. 6.5.5 Sanofi Pasteur Recent Developments
  31. 6.6 Seqirus
  32. 6.6.1 Seqirus Company Information
  33. 6.6.2 Seqirus Business Overview
  34. 6.6.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  36. 6.6.5 Seqirus Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Pfizer Inc
  50. 6.9.1 Pfizer Inc Company Information
  51. 6.9.2 Pfizer Inc Business Overview
  52. 6.9.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  54. 6.9.5 Pfizer Inc Recent Developments
  55. 6.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 6.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 6.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 6.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  60. 6.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 6.11 Novartis AG
  62. 6.11.1 Novartis AG Company Information
  63. 6.11.2 Novartis AG Business Overview
  64. 6.11.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  66. 6.11.5 Novartis AG Recent Developments
  67. 6.12 Johnson & Johnson
  68. 6.12.1 Johnson & Johnson Company Information
  69. 6.12.2 Johnson & Johnson Business Overview
  70. 6.12.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Portfolio
  72. 6.12.5 Johnson & Johnson Recent Developments
7 North America by Country
  1. 7.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  2. 7.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  6. 7.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  2. 8.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  6. 8.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  2. 10.1.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  6. 10.2.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Value Chain Analysis
  2. 12.1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
  7. 12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
  10. 12.2.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst